YOUR INVITATION TO ATTEND:

GeneSight® in Clinical Practice

A MYRIAD GENETICS SPEAKER PRESENTATION

A clinical and scientific discussion focusing on the basics of pharmacogenomics and review of the GeneSight® Psychotropic report and clinical data. Q&A to follow.



PRESENTER

Paul Hill, MD

Dr. Paul B. Hill is a psychiatrist specializing in the treatment of geriatric and medically ill patients in Memphis, Tennessee. Dr. Hill is on the faculty of the University of Tennessee Health Science Center (UTHSC) College of Medicine. He is an Assistant Professor in the Department of Psychiatry where he teaches and trains medical students, and supervises residents and fellows. He received the Golden Apple teaching award in Psychiatry in 1991, the Allen Battle Excellence in Teaching Award in 2015, and Faculty of the Year in 2016, 2017, and 2018. Dr. Hill is experienced with a wide variety of issues related to patient care and directing treatment teams in a medical setting.

DATE & TIME

Thursday, August 8, 2024
6:30pm

LOCATION

Park Heights
335 E Main St.
Tupelo, MS 38801

QUESTIONS

FraLena Davis
Sales Executive
fralena.davis@myriad.com
(901) 289-8823

RSVP

Please RSVP by
August 6, 2024

TO REGISTER

Click Here or scan the QR Code below

This event is not open to the general public. If you were not the original recipient of this invitation, please contact a GeneSight representative with your request to attend.

The GeneSight® Psychotropic test is a genetics-based decision support tool that analyzes clinically important genetic variations that may affect your patient's outcomes with certain psychiatric medications. Use of the GeneSight Psychotropic test can help inform your medication selection. The results show which medications may require dose adjustments, may be less likely to work, or may have an increased risk of side effects based on your patient's genetic makeup. The clinical validity, clinical utility, and economic utility of the GeneSight Psychotropic test have been evaluated in seven published, peer-reviewed clinical trials. In the GUIDED study, patients in the GeneSight arm experienced an 11% relative improvement in symptoms, a 30% relative improvement in response rates, and a 50% relative improvement in remission rates compared to treatment as usual at week 8.

Myriad genetics

6960 Cintas Blvd
Mason, OH 45040
866.260.2394

genesight®
www.genesight.com

MNST.006.216